Isoindoline compounds and methods of their use

1. A compound of Formula (VI):

or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof, wherein:

X is CH 2 or C═O;

m and n are each independently 0 or 1;

p is 0, 1, 2, or 3;

R 81 is 5 to 6 membered heterocyclyl, optionally substituted with C 1-6 alkyl; and

R 82 is hydrogen, C 1-6 alkyl, or halogen.

2. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.

3. A pharmaceutical composition comprising the compound of claim 1 , and one or more pharmaceutically acceptable excipients or carriers.

4. The pharmaceutical composition of claim 3 , further comprising a second therapeutic agent.

5. The pharmaceutical composition of claim 3 , wherein the composition is formulated for single dose administration.

6. The pharmaceutical composition of claim 3 , wherein the composition is formulated as oral, parenteral, or intravenous dosage form.

7. The pharmaceutical composition of claim 6 , wherein the oral dosage form is a tablet or capsule.

8. A method of treating or managing cancer comprising administering to a subject a therapeutically effective amount of a compound of claim 1 , wherein the cancer is Non-Hodgkin's lymphoma, Hodgkin's lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma, or cutaneous T-cell lymphoma.

9. The method of claim 8 , which further comprises administration of one or more additional agents.

10. The method of claim 8 , wherein the compound is administered orally or parenterally.

11. A method of treating or managing cancer comprising administering to a subject a therapeutically effective amount of a compound of claim 1 , wherein the cancer is prostate cancer, pancreatic cancer, breast cancer or colorectal cancer.

12. The method of claim 11 , which further comprises administration of one or more additional agents.

13. The method of claim 11 , wherein the compound is administered orally or parenterally.